Phage-Antibiotic Synergies in Biofilm Infections | Research Webinar

Added:

Antagonistic Interactions and Evolutionary Resistance Risks in Phage-Antibiotic Co-Therapy

While phage-antibiotic synergy (PAS) is a promising strategy, researchers highlight significant challenges and potential downsides to this approach. First, the interaction is not universally synergistic; it can often be antagonistic. For instance, bacteriostatic antibiotics that halt bacterial growth can severely hinder phage replication, as phages require active host cellular machinery to propagate. Second, simultaneous exposure to both agents can drive the rapid evolution of dual resistance. Under pressure from both therapies, bacteria may acquire mutations that confer resistance to both the phage and the antibiotic, or upregulate biofilm matrix production as a generalized defense mechanism. Finally, sub-lethal antibiotic exposure can trigger the bacterial SOS response, potentially promoting horizontal gene transfer where phages inadvertently spread antibiotic resistance or virulence genes among the bacterial population. These limitations suggest that co-therapy is highly context-dependent and carries inherent risks of treatment failure and resistance acceleration if not precisely calibrated.

Structure and composition of bacterial biofilms, including the role of extracellular polymeric substances (EPS) in mediating antibiotic tolerance.
Fundamental bacteriophage biology, specifically the mechanism of the lytic cycle and host specificity.
Standard mechanisms of action for major antibiotic classes and the physiological basis of bacterial antibiotic resistance.
Pharmacological principles of drug interaction, specifically the definitions of synergy, additive effects, and antagonism.
Mechanisms of bacterial resistance to phages and the evolutionary trade-offs that can resensitize bacteria to traditional antibiotics.
Genetic engineering of synthetic phages, such as those engineered to express biofilm-degrading depolymerase enzymes or deliver CRISPR-Cas payloads.
Translational and regulatory hurdles in phage therapy, including FDA/EMA approval pathways, GMP manufacturing, and standardized formulation.
Clinical trial design challenges for personalized medicine, specifically matching phage-antibiotic combinations to patient-specific bacterial isolates.
232 views5likes55:41@BSVoM_officialOriginal Release: 2023-02-17

Phage-antibiotic synergies exploit evolutionary fitness costs, where bacteria developing resistance to one agent become more susceptible to another, making combined treatments more effective than monotherapies for disrupting antibiotic-resistant biofilms; optimal treatment requires simultaneous administration rather than sequential approaches, and serum can inhibit phage efficacy on certain bacterial species.